Efeitos cardiovasculares do citrato de maropitant em cadelas submetidas à ovariosalpingohisterectomia

Abstract

Maropitant citrate is a veterinary antiemetic antagonist NK-1 receptor. This objected study is the investigate cardiovascular changes after administration of the drug and its safety for healthy animals. Used Twenty dog female healthy to submit the elective ovariosalpingohysterectomy. One group received maropitant citrate (1mg / kg) and other received saline solution before premedicated single dose subcutaneously. Was executed electrocardiography, measurement of systolic blood pressure noninvasive, echocardiography and serially before administration (Tpre) and after five minutes to 45 for blood pressure (T0 to T45) and up to 60 for electrocardiography (T5 to T60). After 150 minutes all analyzes were repeated (T150). Only the group receiving placebo had an increase in systolic blood pressure in T150 (p <0.001). Do not observed pathological arrhythmias in the animals the experiment. An increase in the QT interval and QTcorrigido T45, T60 and T150 in maropitant group compared to Tpre and QTcorrigido compared to placebo. The QRS increased compared to T45 Tpre. It found an increase in isovolumetric relaxation time T150 (60 ± 9,94ms) in maropitant group. It is suggested effect calcium channel blocking of potassium and interference in the rigid portion of titin involved in the mechanisms. Not visualized other changes echodopplercardiography associated with myocardial and hemodynamic function. Maropitant citrate can be used in general anesthesia from healthy dogs without changes hemodynamic significant. It should be used with caution in animals showing myocardial repolarization disorders with changes in QT and QTc or diastolic deficits diagnosed previously.